CVS HEALTH Corp - Common Stock (CVS)

Historical Holders from Q1 2014 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: CVS on NYSE
Shares outstanding: 1,268,585,398
Price per share: $79.36
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 1,092,232,854
Total reported value: $82,330,199,357
% of total 13F portfolios: 0.05%
Share change: -966,857
Value change: +$79,413,878
Avg buy value change: +0.01%
Avg sell value change: -0.01%
Number of holders: 1,807
Price from insider filings: $80.13

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of CVS HEALTH Corp - Common Stock (CVS) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	8.3%	+17%	$7,263,082,720	+$1,108,806,594	105,292,588	+18%	BlackRock, Inc.	30 Jun 2025
Capital World Investors	5.5%		$4,534,372,461		68,785,990		Capital World Investors	31 Mar 2025

As of 30 Sep 2025, CVS HEALTH Corp - Common Stock (CVS) has 1,807 institutional shareholders filing 13F forms. They hold 1,092,232,854 shares. of 1,268,585,398 outstanding shares (86%) .

Top 25 institutional shareholders own 61% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	9.4%	119,836,144	-2.3%	0.16%	$9,034,446,910
VANGUARD GROUP INC	9.4%	118,885,106	-1.3%	0.13%	$8,962,748,142
Dodge & Cox	5.8%	73,176,586	-0.15%	3%	$5,516,782,819
Capital World Investors	5.4%	68,382,158	+2.1%	0.7%	$5,155,379,719
STATE STREET CORP	4.6%	58,938,286	+0.25%	0.15%	$4,443,357,382
FMR LLC	3.4%	43,335,261	-5%	0.17%	$3,267,045,296
JPMORGAN CHASE & CO	2.8%	35,275,236	+31%	0.17%	$2,659,421,093
GEODE CAPITAL MANAGEMENT, LLC	2.3%	28,987,765	+1.2%	0.14%	$2,175,513,667
Capital International Investors	2.1%	26,692,203	+1.1%	0.32%	$2,012,347,059
Invesco Ltd.	1.9%	24,293,058	+3.2%	0.29%	$1,831,453,648
MORGAN STANLEY	1.5%	19,162,143	+11%	0.09%	$1,444,634,172
PRICE T ROWE ASSOCIATES INC /MD/	1.4%	17,397,735	+4.7%	0.14%	$1,311,617,000
PZENA INVESTMENT MANAGEMENT LLC	1.2%	15,844,972	-5.4%	3.9%	$1,194,552,439
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	1.1%	13,940,631	+1.1%	0.17%	$1,050,984,863
NORTHERN TRUST CORP	0.96%	12,173,218	-0.03%	0.12%	$917,738,905
Capital Research Global Investors	0.9%	11,469,250	+24%	0.16%	$864,666,758
Davis Selected Advisers	0.9%	11,403,641	-1.6%	4.5%	$859,720,495
BANK OF AMERICA CORP /DE/	0.82%	10,373,682	+6.3%	0.06%	$782,071,875
Legal & General Group Plc	0.73%	9,277,933	+3.3%	0.16%	$699,463,368
Clearbridge Investments, LLC	0.71%	9,031,836	-1.1%	0.51%	$680,885,009
Bank of New York Mellon Corp	0.67%	8,533,512	-1.4%	0.12%	$643,341,452
AMERIPRISE FINANCIAL INC	0.67%	8,448,420	+7.5%	0.15%	$636,954,895
GLENVIEW CAPITAL MANAGEMENT, LLC	0.65%	8,196,799	0%	15%	$617,956,677
ROYAL BANK OF CANADA	0.63%	8,010,558	+0.4%	0.11%	$603,916,000
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC	0.62%	7,924,874	-15%	0.13%	$597,456,252

Institutional Holders of CVS HEALTH Corp - Common Stock (CVS) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	12,752,258	$1,013,358,628	+$265,281,771			$79.36	84
2025 Q3	1,092,232,854	$82,330,199,357	+$79,413,878	$1,672,476,759	$2,030,294,959	$75.39	1,807
2025 Q2	1,095,036,129	$75,500,979,208	+$2,280,399,011	$1,535,263,395	$1,806,979,744	$68.98	1,740
2025 Q1	1,064,718,943	$72,113,884,722	+$1,899,695,324	$1,789,222,052	$1,832,788,898	$67.75	1,731
2024 Q4	1,045,708,735	$46,960,631,407	+$1,004,418,915	$1,229,929,877	$1,386,331,596	$44.89	1,641
2024 Q3	1,014,230,760	$63,831,005,436	-$677,262,119	$1,264,344,456	$1,564,692,992	$62.88	1,823
2024 Q2	1,019,162,974	$60,179,918,934	+$1,060,433,822	$995,324,029	$1,265,533,646	$59.06	1,883
2024 Q1	1,001,904,386	$79,807,139,670	-$1,211,883,033	$1,275,636,342	$1,288,808,184	$79.76	2,137
2023 Q4	1,017,403,858	$80,308,314,517	+$1,281,500,162	$1,123,693,269	$1,397,298,124	$78.96	2,241
2023 Q3	999,658,654	$69,795,638,867	+$491,519,511	$1,124,867,486	$1,358,887,635	$69.82	2,096
2023 Q2	994,552,446	$68,776,049,773	-$267,426,998	$945,093,990	$966,981,549	$69.13	2,184
2023 Q1	992,137,419	$73,734,702,204	-$2,430,332,032	$899,944,076	$884,932,637	$74.31	2,238
2022 Q4	1,027,396,077	$95,710,385,316	-$621,742,148	$1,040,950,580	$1,339,071,838	$93.19	2,386
2022 Q3	1,036,131,117	$98,902,299,567	+$583,699,164	$816,993,358	$1,181,406,456	$95.37	2,306
2022 Q2	1,030,185,027	$95,477,208,943	+$457,242,938	$815,718,938	$998,916,806	$92.66	2,292
2022 Q1	1,028,623,372	$104,166,953,205	-$162,318,215	$1,400,102,960	$1,648,769,837	$101.21	2,350
2021 Q4	1,029,470,276	$106,176,980,983	+$782,593,506	$2,370,618,504	$2,295,672,396	$103.16	2,319
2021 Q3	1,017,132,506	$86,349,876,202	+$21,706,246	$1,985,626,742	$1,820,756,604	$84.86	2,053
2021 Q2	1,017,877,459	$84,919,694,336	+$2,053,435,851	$1,689,871,752	$1,647,653,656	$83.44	2,049
2021 Q1	994,144,506	$74,776,454,186	+$4,878,883	$1,436,599,060	$1,282,664,784	$75.23	2,012
2020 Q4	994,787,112	$67,960,797,654	+$33,414,095	$1,284,754,750	$1,821,804,390	$68.30	1,957
2020 Q3	995,752,919	$58,121,993,856	-$1,243,175,311	$1,069,086,520	$1,667,578,080	$58.40	1,799
2020 Q2	1,014,702,612	$65,855,218,901	+$764,515,206	$984,047,323	$1,628,898,189	$64.97	1,845
2020 Q1	1,004,322,951	$59,576,062,642	-$624,760,654	$973,886,000	$1,728,913,000	$59.33	1,791
2019 Q4	1,009,249,813	$74,949,158,076	+$93,638,735	$1,445,369,000	$1,897,880,000	$74.29	1,826
2019 Q3	1,008,703,801	$63,589,810,377	+$683,854,384	$1,216,933,000	$1,319,324,000	$63.07	1,668
2019 Q2	999,569,687	$54,469,262,379	-$125,833,227	$1,328,109,000	$1,044,477,000	$54.49	1,639
2019 Q1	1,015,392,931	$54,753,892,032	-$2,449,316,890	$1,335,318,000	$1,033,878,000	$53.93	1,688
2018 Q4	1,057,172,458	$69,250,872,296	+$12,127,701,193	$649,542,000	$1,053,006,000	$65.52	1,766
2018 Q3	870,738,435	$68,510,150,212	+$1,883,897,727	$944,732,000	$1,181,886,488	$78.72	1,592
2018 Q2	850,535,070	$54,718,204,845	+$271,208,332	$702,978,000	$786,593,000	$64.35	1,560
2018 Q1	855,048,114	$53,133,760,227	+$40,291,614	$549,649,944	$415,797,945	$62.21	1,540
2017 Q4	853,079,066	$61,782,317,199	+$968,323,049	$881,322,500	$581,936,500	$72.50	1,590
2017 Q3	837,796,253	$68,116,730,466	+$56,831,988	$452,785,000	$439,420,000	$81.32	1,521
2017 Q2	837,689,880	$67,390,063,873	-$462,380,881	$507,808,000	$466,042,000	$80.46	1,543
2017 Q1	844,552,702	$66,288,166,171	+$3,453,423,579	$1,072,096,000	$1,082,355,000	$78.50	1,567
2016 Q4	864,216,464	$68,187,625,679	-$1,218,453,807	$671,590,000	$590,356,000	$78.91	1,538
2016 Q3	875,715,124	$77,884,446,974	+$259,099,282	$364,743,000	$458,392,000	$88.99	1,549
2016 Q2	873,506,079	$83,618,862,892	-$2,313,703,183	$294,289,000	$346,643,000	$95.74	1,561
2016 Q1	893,044,162	$92,609,940,962	-$2,342,978,344	$229,864,000	$353,561,000	$103.73	1,545
2015 Q4	918,665,396	$89,872,788,969	-$1,169,382,817	$446,871,000	$510,650,700	$97.77	1,546
2015 Q3	930,649,306	$89,772,711,977	+$452,661,446	$459,619,000	$393,326,800	$96.48	1,495
2015 Q2	932,490,480	$97,801,341,585	-$527,179,116	$325,531,000	$387,524,000	$104.88	1,474
2015 Q1	938,923,116	$96,891,534,061	-$2,012,979,554	$264,383,000	$362,167,000	$103.21	1,445
2014 Q4	959,101,291	$92,389,718,105	-$1,177,070,671	$381,150,000	$340,160,000	$96.31	1,405
2014 Q3	967,787,030	$77,023,824,218	-$334,904,756	$230,981,597	$216,153,000	$79.59	1,279
2014 Q2	967,892,104	$72,951,405,364	-$1,478,437,398	$152,373,000	$229,101,000	$75.37	1,257
2014 Q1	988,119,670	$73,935,267,317	-$591,640,692	$197,388,000	$220,888,000	$74.86	1,222